Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse product line includes liquid oral medications, cephalosporin-based drugs (available as tablets, capsules, and dry powder syrups), various injectable forms such as dry powder injections, and liquid injectable solutions (supplied in ampoules, vials, and lyophilized preparations), alongside oral solid dosages. Their comprehensive portfolio addresses approximately 22 distinct therapeutic categories, encompassing treatments for conditions like acidity, malaria, blood clotting, constipation, respiratory issues, pain, infections, depression, allergies, and nutritional deficiencies, among others. Sakar Healthcare also has a significant global reach, distributing its products to roughly 38 countries across regions including Southeast Asia, other parts of Asia, both English and French-speaking African nations, the Middle East and North Africa, and the United States.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA